The "Valley of Death" in pharmaceutical R&D is being accelerated by AI technology. In February 2026, the pioneer in translational medicine Hangzhou Huiyidao Technology Co., Ltd. officially announced a comprehensive brand upgrade, launching with the new identity of "AIMed" on the global stage, committed to becoming an intelligent connector and enabler in the field of translational medicine.

Core Mission: Bridging the Gap Between "Laboratory" and "Clinical"

AIMed was founded by Jin Xia, a member of the Zhejiang Provincial Committee of the Chinese People's Political Consultative Conference and an expert in the health industry. The core of this brand upgrade lies in deepening the application of AI in the field of translational medicine, using technological means to make scientific discoveries in the laboratory more efficiently translated into clinical treatment solutions.

Key Product: PharmaMark AI Paves the Way for Pharmaceutical Companies Going Global

At the same time of the brand upgrade, its core product PharmaMark AI has demonstrated strong commercial certainty:

  • Patent Alert: Utilizing AI to deeply analyze global patent landscapes, helping Chinese pharmaceutical companies accurately identify overseas patent litigation risks.

  • Risk Reduction: Intervening at an early stage of drug development to effectively avoid infringement risks and clear compliance obstacles for new drugs entering the international market.

  • Enhanced Conversion Rate: By leveraging data-driven decision support, significantly improving the overall success rate of translational medicine and shortening the drug launch cycle.

Technical Endorsement: FDA Certified, Algorithms Leading Globally

AIMed has steadily built its technical barriers since its establishment in 2019:

  • Top-tier Collaboration: Collaborating with multiple top research institutions worldwide to develop patent algorithms.

  • Authoritative Certification: The relevant technologies have obtained certification from the U.S. FDA (Food and Drug Administration), proving their professionalism and compliance in the medical AI field.

  • Agent Practice: As a leading practitioner of AI agent products in translational medicine, AIMed plans to release more vertical scenario AI applications within 2026.

Industry Insight:

In today's increasingly competitive pharmaceutical industry, AIMed's brand upgrade indicates that "AI + translational medicine" has entered a stage of refined implementation. From general large models to AI experts in specific fields, technology platforms like AIMed that provide "certainty" will become key variables in reducing costs and improving efficiency in new drug development.